Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nereid study of MCA-derived mesenchymal stromal cells after kidney transplantation
NL-OMON53310Not yet recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2023
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label trial of MCA-derived mesenchymal stromal cells and tacrolimus in kidney allograft rejection and Kidney allograft dysfunction, sponsored by Leiden University Medical Center. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
MCA-derived mesenchymal stromal cellstacrolimus
03
Conditions
kidney allograft rejectionKidney allograft dysfunction
Beyond the preview
Go deeper on NL-OMON53310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53310.